Celiac Panel Longevity-Medicine Target Ranges

What the Celiac Panel Actually Measures

A celiac panel is not a single test. It is a tiered antibody screen that checks for immune reactivity to gluten-derived proteins and to the self-antigen tissue transglutaminase 2 (TG2). The four components most commonly ordered together are tTG-IgA, total serum IgA, DGP-IgA, and DGP-IgG. EMA-IgA is added as a reflex or confirmatory step in many laboratory protocols.

Understanding what each marker detects helps explain why a longevity-focused clinician treats borderline values differently than a conventional gastroenterology workup focused only on overt disease.

tTG-IgA: The First-Line Marker

Tissue transglutaminase IgA is the single highest-yield initial test. The enzyme TG2 is expressed throughout the small intestinal mucosa and cross-links gliadin peptides, creating neo-epitopes that trigger the adaptive immune response in genetically susceptible individuals (HLA-DQ2 or HLA-DQ8 carriers). The 2023 American College of Gastroenterology (ACG) Clinical Guideline states: "tTG-IgA is the preferred single serologic test for celiac disease detection in patients with normal total serum IgA levels and is recommended as the first-line test in both symptomatic and at-risk populations." [1]

Most commercial laboratories flag tTG-IgA as positive at or above 15 U/mL. In longevity medicine, values between 4 and 14 U/mL are treated as a gray zone requiring follow-up rather than reassurance.

Total Serum IgA: The Essential Co-Test

Selective IgA deficiency occurs in roughly 1 in 300 to 1 in 500 people in the general population, but in patients with celiac disease the prevalence rises to approximately 1 in 39. [2] When total IgA is low, tTG-IgA, EMA-IgA, and DGP-IgA all return falsely negative. Ordering tTG-IgA without total IgA produces a panel that cannot be interpreted.

The 2019 European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guidelines define IgA deficiency as a total serum IgA below 0.07 g/L in individuals older than 4 years. [3] When deficiency is confirmed, the panel shifts to DGP-IgG, which remains valid.

DGP Antibodies: The IgA-Deficient Patient's Safety Net

Deamidated gliadin peptide antibodies (DGP-IgA and DGP-IgG) target the same gliadin fragments but use a different immunoglobulin class. DGP-IgG has sensitivity of approximately 80% and specificity of approximately 98% in IgA-deficient patients. [4] In adults with normal IgA, DGP adds little incremental diagnostic yield over tTG-IgA alone, but in children under 2 years, DGP-IgA may rise before tTG-IgA does, making it useful in pediatric screening protocols.

EMA-IgA: The Confirmatory Reflex

Endomysial antibody IgA, detected by indirect immunofluorescence on primate esophagus or human umbilical cord, has specificity exceeding 99% in most published series. [5] Because EMA testing is labor-intensive and operator-dependent, it is used as a reflex confirmatory test rather than a first-line screen. A positive EMA in the context of elevated tTG-IgA raises the pre-biopsy probability of villous atrophy to more than 95%.

Standard Lab Reference Ranges vs. Longevity-Medicine Target Ranges

Standard reference intervals are set to minimize false positives in population screening. They are not optimized for early detection in asymptomatic high-risk individuals. The table below compares conventional cutoffs with longevity-medicine targets used at HealthRX.

| Marker | Conventional "Negative" Cutoff | Longevity-Medicine Target | |---|---|---| | tTG-IgA | <15 U/mL | <4 U/mL | | Total serum IgA | 70 to 400 mg/dL (adult) | 100 to 350 mg/dL | | DGP-IgA | <20 U/mL | <7 U/mL | | DGP-IgG | <20 U/mL | <7 U/mL | | EMA-IgA | Negative | Negative |

The rationale for tightening the tTG-IgA target to below 4 U/mL comes from biopsy data. A 2016 prospective cohort study (N=463) published in the American Journal of Gastroenterology found that tTG-IgA values in the 4 to 10 U/mL range were associated with Marsh I to II mucosal changes (intraepithelial lymphocytosis without villous atrophy) in 38% of patients who underwent biopsy. [6] Subclinical mucosal inflammation at this level may impair nutrient absorption for years without triggering a formal celiac diagnosis.

Why Celiac Serology Belongs in a Longevity Panel

Celiac disease is the most common autoimmune condition driven by a known environmental antigen. Left undiagnosed, it produces a cascade of downstream deficiencies and comorbidities that compound over decades. Three of those downstream effects are especially relevant to longevity medicine.

Iron Deficiency Without an Obvious Cause

The proximal small intestine (duodenum and proximal jejunum) is both the primary site of iron absorption and the primary site of gluten-driven villous atrophy. A 2021 systematic review in Clinical Gastroenterology and Hepatology (pooled N=7,834) found that iron deficiency anemia was present in 32% of adults at celiac diagnosis, and in 46% of those presenting without gastrointestinal symptoms. [7] Treating iron deficiency without identifying the absorptive lesion produces only transient improvement. The serum ferritin returns to baseline within months.

Clinicians evaluating unexplained iron deficiency should order a celiac panel as part of the first-line workup, not as a late reflex after multiple courses of oral iron fail.

Vitamin B12 Depletion

Ileal disease in celiac patients is less common than duodenal involvement, but mucosal inflammation extending distally impairs intrinsic factor binding and B12 absorption over time. A cross-sectional study in the European Journal of Gastroenterology and Hepatology (N=1,032) reported B12 deficiency in 19% of newly diagnosed celiac adults. [8] B12 depletion at the cellular level drives hyperhomocysteinemia, peripheral neuropathy risk, and accelerated cognitive aging. Catching celiac serology early is one of the few reversible causes of elevated homocysteine.

Autoimmune Thyroid Disease Overlap

The co-occurrence of celiac disease and autoimmune thyroid conditions (Hashimoto thyroiditis and Graves disease) is well established. A 2019 meta-analysis in Thyroid (14 studies, N=20,118) calculated that celiac disease prevalence in autoimmune thyroid patients was 3.3%, compared with 0.6% in controls, representing a roughly 4-fold excess risk. [9] The shared HLA-DQ2/DQ8 haplotype and a common intestinal permeability mechanism are the proposed biological links.

The clinical implication is direct: any patient with Hashimoto thyroiditis whose levothyroxine dose keeps rising despite apparent adherence should have celiac serology reviewed. Malabsorption of levothyroxine in the inflamed duodenum is a documented mechanism of refractory hypothyroidism. [10]

Interpreting Borderline and Weakly Positive Results

A tTG-IgA between 4 and 14 U/mL occupies the most clinically contested zone in celiac testing. Standard laboratory reports call this "negative." Longevity-medicine protocols treat it as "indeterminate pending follow-up."

The Weakly Positive tTG-IgA: A Three-Step Response

1. Confirm total serum IgA is within range to validate the tTG-IgA result.
2. Reflex to EMA-IgA. A positive EMA in the 4 to 14 U/mL tTG-IgA zone raises the likelihood of Marsh I-II changes to approximately 60 to 70%.
3. Order HLA-DQ2/DQ8 typing. A negative HLA result (absent DQ2 and DQ8) makes celiac disease biologically improbable regardless of tTG-IgA level. A positive HLA result combined with weakly elevated tTG-IgA justifies gastroenterology referral for duodenal biopsy.

This approach is consistent with the ACG 2023 guideline recommendation: "In individuals with tTG-IgA values 1 to 3 times the upper limit of normal, EMA-IgA testing or HLA typing may be used to guide the need for duodenal biopsy." [1]

When the Panel Is Negative but Clinical Suspicion Remains High

A negative panel on a patient currently eating a gluten-free diet is not a reassuring result. It is an uninterpretable result. The ACG guideline explicitly states that patients must be consuming gluten for at least 6 weeks before serologic testing, with at least two to three servings of gluten per day. [1] Any patient who reports dietary modification before testing should have the panel repeated after a formal 6-week gluten challenge. This is the most common source of false-negative celiac serology in clinical practice.

Monitoring After a Celiac Diagnosis: Longevity Targets on a Gluten-Free Diet

Diagnosis is not the endpoint. Serial celiac serology is used to verify dietary adherence and mucosal recovery. The tTG-IgA normalizes in most adherent adults within 12 to 24 months of strict gluten elimination. A 2020 follow-up study in Alimentary Pharmacology and Therapeutics (N=306) found that patients with persistent tTG-IgA above 6 U/mL at 12 months of a gluten-free diet had a 2.4-fold higher risk of persistent villous atrophy on repeat biopsy compared with those who normalized to below 4 U/mL. [11]

Recommended Monitoring Schedule in Longevity Medicine

• At 6 months after starting a gluten-free diet: repeat tTG-IgA and DGP-IgA.
• At 12 months: repeat full panel plus ferritin, B12, 25-OH vitamin D, and a thyroid panel.
• At 24 months: repeat full panel plus bone mineral density (DXA) if not yet obtained at diagnosis.
• Annually thereafter: tTG-IgA alone is sufficient if values are stable below 4 U/mL.

Nutrient Repletion Targets on a Gluten-Free Diet

A gluten-free diet corrects the absorptive lesion but does not immediately correct the nutrient deficits that accumulated before diagnosis. Target levels for longevity medicine include:

• Ferritin: 50 to 150 ng/mL (not merely "above 12," the conventional lower limit of normal).
• Serum B12: 400 to 900 pg/mL.
• 25-OH vitamin D: 40 to 60 ng/mL.
• Folate: above 10 ng/mL.

A 2022 cross-sectional study in Nutrients (N=214) found that 41% of celiac patients on a long-term gluten-free diet for more than 2 years still had ferritin below 50 ng/mL, suggesting that dietary correction alone is insufficient for many patients. [12]

Genetic Context: HLA-DQ2 and HLA-DQ8 in Longevity Risk Stratification

Approximately 95% of celiac patients carry HLA-DQ2 (most commonly the DQ2.5 heterodimer encoded by HLA-DQA105 and HLA-DQB102), and nearly all of the remaining 5% carry HLA-DQ8. [13] Neither HLA variant causes celiac disease on its own. About 30% of the general population carries DQ2 or DQ8, but only about 3% of those carriers develop clinical celiac disease in their lifetime.

HLA typing in longevity medicine is used primarily for exclusion. A patient who carries neither DQ2 nor DQ8 has a negative predictive value for celiac disease above 99.7%, which is high enough to confidently deprioritize further celiac evaluation even when other autoimmune markers are mildly elevated. [14]

HLA positivity, by contrast, stratifies lifetime risk and justifies periodic repeat serology (every 2 to 3 years) in asymptomatic carriers with strong family history or coexisting autoimmune conditions.

Celiac Panel in the Context of a Full Longevity Lab Review

The celiac panel does not exist in isolation. In a longevity medicine context, it is interpreted alongside several related panels.

The Iron-Celiac-Thyroid Triad

Iron deficiency suppresses thyroid peroxidase activity, blunts the response to levothyroxine, and impairs conversion of T4 to T3. Celiac disease is one of the few conditions that simultaneously drives all three abnormalities through a single mechanism: proximal small intestinal villous atrophy reducing iron, B12, zinc, and selenium absorption in parallel.

A clinician evaluating low ferritin, elevated TSH, and a rising levothyroxine requirement in the same patient should always check celiac serology before attributing the findings to independent processes.

When to Add Non-Celiac Gluten Sensitivity Testing

Non-celiac gluten sensitivity (NCGS) is a clinical diagnosis of exclusion. There is no validated biomarker. NCGS does not produce the elevated tTG-IgA, positive EMA, or villous atrophy seen in celiac disease. A negative celiac panel does not rule out NCGS. Patients with persistent gastrointestinal or neurological symptoms that resolve on a gluten-free diet but who test negative on a full celiac panel and lack HLA-DQ2/DQ8 may have NCGS. Management is identical (strict gluten-free diet), but the monitoring schedule differs because mucosal damage is not part of the pathophysiology. [15]

Wheat Allergy Versus Celiac Disease

Wheat allergy is IgE-mediated and is detected by skin-prick testing or serum wheat-specific IgE, not by the celiac panel. A positive tTG-IgA does not diagnose wheat allergy; a positive wheat IgE does not diagnose celiac disease. Both can coexist. In an athlete or patient using wheat protein supplementation, distinguishing these two conditions changes dietary counseling and repletion strategy significantly.

Practical Ordering Guidance for Clinicians

Order the four-marker panel as a unit: tTG-IgA, total serum IgA, DGP-IgA, and DGP-IgG. Do not order tTG-IgA alone. Ordering tTG-IgA without total serum IgA misses the IgA-deficient patient who will test falsely negative.

Pre-test requirements matter. The patient must be on a gluten-containing diet for at least 6 weeks prior to the draw. Two to three servings of gluten per day (equivalent to roughly four slices of standard bread) is the standard challenge amount per ACG 2023 guidelines. [1]

Sample type is whole blood drawn into a serum separator tube (SST). Fasting is not required. Hemolysis does not affect the antibody assays, but highly lipemic samples may require repeat testing at some laboratories.